1FW

AUG 0 7 2006 &

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Case No.: 02-728-L (400/166US))

In the Application of:

McSwiggen, et al.

10/562,561

Filed:

Serial No.:

December 27, 2005

For: RNA Interference Mediated Treatment of Alzheimer's Disease Using Short Interfering Nucleic Acid (siNA) Art Unit: TBA

Examiner: Not assigned

Conf. No. 3830

TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In regard to the above-identified application:

- 1. We are transmitting herewith the attached
 - a. PTO Form 1449;
 - b'. Two (2) cited references; and
 - c Return Receipt Postcard
- 2. It is believed no fee is due at this time. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2490. A duplicate copy of this sheet is enclosed.

3. CERTIFICATE OF MAILING UNDER 37 CFR §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on August 2, 2006.

Respectfully submitted,

Date: August 2, 2006

By:

Lisa M.W. Hillman, Ph.D

Reg. No. 43,673

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Tradelliais Office, so U.S. Patent and Tr

Spstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 10/562,561 December 27, 2005 Filing Date McSwiggen First Named Inventor **TBA** Art Unit **Examiner Name** ТВА

(Use as many sheets as necessary) 02-728-L (400.166US) Attorney Docket Number Sheet

			U. S. PATENT	DOCUMENIS	Outures Lines Where
Examiner	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
Initials*	INO.	Number-Kind Code ^{2 (if known)}		15	
	*	us- 2003/0232435	12-2003	Dobie	
	*	us- 5,998,203	12-1999	Matulic-Adamic	
	*	us- 6,046,320	04-2000	Monia et al.	
	*	US- 2002/0151693	10-2002	Breaker et al.	
		US-			
	1	US-			
		US			
		US-			
		US- 3"			

		FOREIGN P	ATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
	*	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known) WO 94/01550	01-1994	Agrawal et al.	·	-
	 					+
	+			<u> </u>	<u> </u>	<u></u>

I			<u> </u>		
ļ				1 Date	
1	Examiner			Considered	
ļ	Signature		W MOED 600 F	Providing through ci	tation if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the This collection of information is required by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspect of the confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspect of the confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspect of the confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspect of the confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, use of the confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, use of the complete of the comp on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 06/30/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

14400,000		Complete if Known
Substitute for form 1449B/PTO	Application Number	10/562,561
INFORMATION DISCLOSURE	Filing Date	December 27, 2005
	First Named Inventor	McSwiggen
STATEMENT BY APPLICAN	Art Unit	TBA
(Use as many sheets as necessary)	Examiner Name	TBA
Sheet 2 of 2	Attorney Docket Number	02-728-L

		NON PATENT LITERATURE DOCUMENTS					
Examiner nitials*	Cite No.1						
		Shaw et al., (1991) Nucleic Acids Res. 19:747-750					
	 	Snaw et al., (1991) Nucleic Acids Nos. 1911					
	*	Chang et al., (1999) J. Mol. Neuroscience 12:69-74	├				
	1	GenBank Accession No. CQ989002, January 25, 2005	<u> </u>				
	╬	Gelibalik Accession no. o george					
	2	GenBank Accession No. NM_000484 October 31, 2000 Schmidt et al., "Bases and sugar requirements for RNA cleavage of essential nucleoside schmidt et al., "Bases and sugar requirements for RNA cleavage of essential nucleoside schmidt et al., "Bases and sugar requirements for RNA cleavage of essential nucleoside schmidt et al., "Bases and sugar requirements for RNA cleavage of essential nucleoside schmidt et al., "Bases and sugar requirements for RNA cleavage of essential nucleoside schmidt et al.,"	†				
		Schmidt et al., "Bases and sugar requirements for KNA cleavage of secondary structure", residues in internal loop B of the hairpin ribozyme: implications for secondary structure",	1				
	*	Nucleic Acids Research, 1996, Vol. 24, No. 4:573-581	+-				
		Caplen NJ, "RNAi as a Gene Therapy Approach", Expert Opinion Biol. Thera. (2003) Vol.	١.				
	*	3(4):575-586					
		Hammond et al., "Post-transcriptional gene silencing by double-stranded RNA" Nature,					
	*	2001, Vol. 2, 110-119					
			\perp				
			十				
		·.					
Evaminer		Date					

Signature * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

Examiner

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, uspection of the uspection of the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chie ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.